This company has been acquired
bluebird bio (BLUE) Aandelenoverzicht
bluebird bio, Inc., een biotechnologiebedrijf, onderzoekt, ontwikkelt en verkoopt gentherapieën voor genezende ernstige genetische ziekten in de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 0/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
BLUE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
bluebird bio, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$4.97 |
| 52 Week Hoogtepunt | US$28.60 |
| 52 Week Laag | US$3.20 |
| Bèta | 0.32 |
| 1 maand verandering | 21.81% |
| 3 maanden verandering | 21.81% |
| 1 Jaar Verandering | -72.49% |
| 3 jaar verandering | -92.14% |
| 5 jaar verandering | -99.65% |
| Verandering sinds IPO | -99.08% |
Recent nieuws en updates
High Noon For bluebird
Summary bluebird bio faces imminent bankruptcy unless a deal closes; current offer is $5 cash or $3 plus a low-value CVR. A rival bidder, Ayrmid, previously offered $4.50 plus the same CVR, but financing delays stalled a superior deal. If Ayrmid returns with a $6.50 all-cash offer before Tuesday, shareholders could see a bidding war; time is critical. At ~$5 per share, risk/reward is highly asymmetric—downside is limited, upside could be significant if a bidding war emerges. Read the full article on Seeking Alpha
Patient Starts And Capacity Expansion Will Achieve Breakeven
Sustained patient demand and operational efficiency improvements are poised to enhance revenue growth and financial stability by driving cash flow breakeven.Recent updates
High Noon For bluebird
Summary bluebird bio faces imminent bankruptcy unless a deal closes; current offer is $5 cash or $3 plus a low-value CVR. A rival bidder, Ayrmid, previously offered $4.50 plus the same CVR, but financing delays stalled a superior deal. If Ayrmid returns with a $6.50 all-cash offer before Tuesday, shareholders could see a bidding war; time is critical. At ~$5 per share, risk/reward is highly asymmetric—downside is limited, upside could be significant if a bidding war emerges. Read the full article on Seeking AlphaPatient Starts And Capacity Expansion Will Achieve Breakeven
Sustained patient demand and operational efficiency improvements are poised to enhance revenue growth and financial stability by driving cash flow breakeven.Investors Don't See Light At End Of bluebird bio, Inc.'s (NASDAQ:BLUE) Tunnel And Push Stock Down 38%
bluebird bio, Inc. ( NASDAQ:BLUE ) shareholders won't be pleased to see that the share price has had a very rough...bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors
With a price-to-sales (or "P/S") ratio of 1.3x bluebird bio, Inc. ( NASDAQ:BLUE ) may be sending very bullish signals...bluebird bio: Scientific Success And Financial Success, And The Gap Between
Summary Back in 2019 and early 2020, bluebird bio stock was between $40 and $50 a share, and the latest quote is 48 cents. This despite getting three gene therapies on the market. Two of bluebird bio’s gene therapies, Zentego and Lyfgenia, compete with Casgevy from Vertex Pharmaceuticals and CRISPR Therapeutics, which is approved for basically the same patient populations. The company is cutting staff, especially in R&D, in order to focus on commercial operations. But whether that will work is unknown. Read the full article on Seeking Alphabluebird bio's Flight Through Financial Fog And Fierce Rivals
Summary bluebird bio, Inc. stock plummeted by 73% amid financial struggles and operational hurdles post FDA approval of their gene therapy Lyfgenia. The company faces intense competition from CRISPR Therapeutics' Casgevy, which benefits from stronger resources and a faster market rollout. Recent financial disclosures are incomplete, obscuring a clear view of bluebird's financial health and prolonging investor uncertainty. Maintain a sell recommendation on bluebird bio due to substantial financial and operational risks, with a cautious note on potential high volatility. Read the full article on Seeking Alphabluebird bio Is Priced Below IP Value
Summary bluebird bio's stock price has dropped 64% due to safety warnings and high pricing for their sickle cell treatment. The company's intellectual property alone suggests a potential sale value of $300-320 million, higher than its current market cap of $280 million. bluebird bio has extended its cash runway and has the potential to achieve profitability within the next year. Read the full article on Seeking AlphaBluebird Bio: Innovative Therapies, Monetary Setbacks
Summary More than one year into the Launch of Zynteglo and Skysona, BLUE's sales remain underwhelming. The company launched a third gene therapy, Lyfgenia, but faces similar commercialization challenges. High treatment costs, limited patient base, outsourced production, long-term follow-up studies, and intensifying competition are all factors that obscure BLUE's path to profitability. Read the full article on Seeking AlphaIs bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo
Real Endpoints said it is collaboration with bluebird bio (NASDAQ:BLUE) to provide multiple health plans with access to an outcomes-based agreement for β-thalassemia gene therapy Zynteglo through the Real Endpoints (RE) Marketplace. Zynteglo, which is approved to treat patients with beta-thalassemia who require regular blood transfusions, is priced at $2.8M for a one-time therapy, making it the most expensive treatment in history. Real noted that these plans cover ~16M people in the U.S. Through a single contract, the plans in RE Marketplace can take immediate advantage of bluebird's agreement, which offers rebates of up to 80% if treatment with Zynteglo does not enable a patient to achieve and maintain transfusion independence in two years following therapy, Real said in an Oct. 4 press release. "The plans in RE Marketplace are thrilled to be able to easily access bluebird’s innovative risk-sharing agreement, which speeds the delivery of both clinical and economic innovations," said Real's Chief Clinical Officer Jane Barlow. BLUE +2.77% to $6.30 premarketBluebird bio names interim finance chief
Gene therapy developer bluebird bio, Inc. (NASDAQ:BLUE) has named Katherine Breedis, formerly the Chief Financial Officer Consultant at Danforth Advisors, as the company’s interim Chief Financial Officer replacing the outgoing CFO Jason Cole. Ms. Breedis has also been named as BLUE’s principal financial officer and principal accounting officer, and her appointments will take effect on Oct. 14 when Mr. Cole departs. Ms. Breedis, who has worked as a CFO consultant for Danforth since Jul. 2021, served as a consultant to BLUE after the company struck a consulting agreement with the advisory firm in May. Mr. Cole’s departure came less than a month after the FDA approved BLUE’s β-thalassemia therapy Zynteglo in August, making it the priciest treatment in history at the time.Bluebird bio jumps 17% on FDA approval of new gene therapy
The commercial-stage biotech bluebird bio, Inc. (NASDAQ:BLUE) added ~17% pre-market Monday after the company announced the FDA approval of its gene therapy Skysona to address the impact of a rare neurodegenerative disease called cerebral adrenoleukodystrophy (CALD). According to the late Friday press release, the drug, also known as elivaldogene autotemcel (eli-cel), will be indicated in the U.S. to slow the progression of neurologic dysfunction in boys aged 4-17 with early, active CALD. With the FDA approving Skysona under the agency’s accelerated approval pathway, BLUE has agreed to deliver long-term clinical data on the treatment to the regulator, including data from an ongoing long-term follow-up study and commercially treated patients. The company expects the drug to be commercially available by the end of 2022 at a list price of $3.0M. Concurrently, BLUE confirmed that the FDA had lifted the clinical hold on the eli-cel development program. In August, Cambridge, Massachusetts-based biotech won FDA approval for another gene therapy known as Zynteglo for β-thalassemia which it priced at $2.8M.bluebird bio' chief strategy and financial officer to depart
Jason Cole, chief strategy and financial officer of bluebird bio (NASDAQ:BLUE), plans to leave the firm, effective Oct 14, 2022, to pursue new career opportunities. Mr. Cole spent 8.5 years at bluebird, serving in multiple roles including general counsel/chief legal officer, chief operating & legal officer and chief business officer. He took the chief strategy and financial officer role in Mar 2022, leading changes to stabilize the firm's financial position and strengthen its balance sheet. bluebird (BLUE) has initiated an external search for its next CFO. In the meantime, Katherine Breedis, an experienced business and financial executive from Danforth Advisors, is expected to serve as interim CFO. Cole is expected to continue to consult with the company on corporate strategy through April 2023.Rendement voor aandeelhouders
| BLUE | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -0.4% | 1.1% | 1.5% |
| 1Y | -72.5% | 35.8% | 28.6% |
Rendement versus industrie: BLUE presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 35.8 % opleverde.
Rendement versus markt: BLUE presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 28.6 % opleverde.
Prijsvolatiliteit
| BLUE volatility | |
|---|---|
| BLUE Average Weekly Movement | 17.4% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stabiele aandelenkoers: De aandelenkoers van BLUE is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van BLUE is het afgelopen jaar gedaald van 23% naar 17%, maar is nog steeds hoger dan 75% van de US -aandelen.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1992 | 248 | Andrew Obenshain | www.bluebirdbio.com |
bluebird bio, Inc., een biotechnologiebedrijf, onderzoekt, ontwikkelt en commercialiseert gentherapieën voor curatieve ernstige genetische ziekten in de Verenigde Staten. De productkandidaten van het bedrijf voor ernstige genetische ziekten omvatten ZYNTEGLO (betibeglogene autotemcel) voor de behandeling van transfusie-afhankelijke ß-thalassemie; LYFGENIA (lovotibeglogene autotemcel) voor de behandeling van sikkelcelziekte (SCD) en een voorgeschiedenis van vaso-occlusieve gebeurtenissen; en SKYSONA (elivaldogene autotemcel) voor de behandeling van cerebrale adrenoleukodystrofie. Haar klinische ontwikkelingsprogramma's omvatten HGB-205, HGB-206 en HGB-210 om de veiligheid en doeltreffendheid van lovo-cel te evalueren bij de behandeling van patiënten met SCD; en HGB-204, HGB-205, HGB-207 en HGB-212 om de veiligheid en doeltreffendheid van beti-cel te evalueren bij de behandeling van patiënten met ß-thalassemie.
bluebird bio, Inc. Samenvatting
| BLUE fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$48.67m |
| Inkomsten(TTM) | -US$199.98m |
| Inkomsten(TTM) | US$103.95m |
Is BLUE overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| BLUE resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$103.95m |
| Kosten van inkomsten | US$75.75m |
| Brutowinst | US$28.19m |
| Overige uitgaven | US$228.17m |
| Inkomsten | -US$199.98m |
Laatst gerapporteerde inkomsten
Mar 31, 2025
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -20.42 |
| Brutomarge | 27.12% |
| Nettowinstmarge | -192.39% |
| Schuld/Eigen Vermogen Verhouding | -175.5% |
Hoe presteerde BLUE op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2025/05/30 13:31 |
| Aandelenkoers aan het einde van de dag | 2025/05/30 00:00 |
| Inkomsten | 2025/03/31 |
| Jaarlijkse inkomsten | 2024/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
bluebird bio, Inc. wordt gevolgd door 21 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Zhiqiang Shu | Berenberg |
| Vincent Chen | Bernstein |
| Matthew Luchini | BMO Capital Markets Equity Research |